Targeting the 5T4 oncofoetal glycoprotein with an antibody drug conjugate (A1mcmmaf) improves survival in patient derived xenograft models of acute lymphoblastic leukemia.
AffiliationUniversity of Manchester, Manchester, UK
MetadataShow full item record
AbstractOutcome in childhood acute lymphoblastic leukemia is prognosticated on levels of minimal residual disease after remission induction therapy. Higher minimal residual disease levels are associated with inferior results even with intensification of therapy and suggest identification and targeting of minimal residual disease cells as a therapeutic strategy. Here we identify high expression of 5T4 in subclonal populations of patient derived xenografts from patients with high minimal residual disease post induction. 5T4 positive cells showed preferential ability to overcome the NOD-scidIL2Rγnull mouse xenograft barrier; migrated in vitro on a CXCL12 gradient; preferentially localised to bone marrow in vivo and displayed ability to reconstitute the original clonal composition on limited dilution engraftment. Treatment with A1mcMMAF (5T4-Antibody Drug conjugate) significantly improved survival without overt toxicity in mice engrafted with a 5T4 positive acute lymphoblastic leukemia cell line. Mice engrafted with 5T4 positive patient derived xenograft cells, were treated with combination chemotherapy or dexamethasone alone and then given A1mcMMAF in the minimal residual disease setting. Combination chemotherapy was toxic to NOD-scidIL2Rγnull mice. While dexamethasone or A1mcMMAF alone improved outcomes, the sequential administration of dexamethasone and A1mcMMAF significantly improved survival (p=0.0006) over either monotherapy. These data show specifically targeting minimal residual disease cells improved outcomes supporting further investigation of A1mcMMAF in high risk B- cell precursor-acute lymphoblastic leukemia patients identified by 5T4 at diagnosis.
CitationTargeting the 5T4 oncofoetal glycoprotein with an antibody drug conjugate (A1mcmmaf) improves survival in patient derived xenograft models of acute lymphoblastic leukemia. 2017, 102: Haematologica
- Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells.
- Authors: Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, Golas J, Dougher M, Narayanan B, Giannakou A, Khandke K, Dushin R, Ernstoff E, Lucas J, Leal M, Hu G, O'Donnell CJ, Tchistiakova L, Abraham RT, Gerber HP
- Issue date: 2013 Jan
- Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer.
- Authors: Wan YL, Sapra P, Bolton J, Chua JX, Durrant LG, Stern PL
- Issue date: 2019 Aug
- 5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype.
- Authors: Castro FV, McGinn OJ, Krishnan S, Marinov G, Li J, Rutkowski AJ, Elkord E, Burt DJ, Holland M, Vaghjiani R, Gallego A, Saha V, Stern PL
- Issue date: 2012 Jul
- Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
- Authors: Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE, Inaba H, Bhojwani D, Gruber TA, Leung WH, Downing JR, Evans WE, Relling MV, Campana D
- Issue date: 2015 Apr
- Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
- Authors: Paul S, Rausch CR, Kantarjian H, Jabbour EJ
- Issue date: 2017 Oct